Cargando…

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huarte, Eduardo, Peel, Michael T., Verbist, Katherine, Fay, Brittany L., Bassett, Rachel, Albeituni, Sabrin, Nichols, Kim E., Smith, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107823/ https://www.ncbi.nlm.nih.gov/pubmed/33981229 http://dx.doi.org/10.3389/fphar.2021.650295

Ejemplares similares

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis
por: Shapiro, Leland, et al.
Publicado: (2022)

Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19
por: Peter, Angela E., et al.
Publicado: (2021)

Ameliorative Effects of Dietary Ellagic Acid Against Severe Malaria Pathogenesis by Reducing Cytokine Storms and Oxidative Stress
por: Mohanty, Shilpa, et al.
Publicado: (2021)

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm
por: Botta, Cirino, et al.
Publicado: (2021)

Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability
por: Mantov, Nikola, et al.
Publicado: (2022)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)

Immunotherapy Summary for Cytokine Storm in COVID-19
por: Li, Yaqun, et al.
Publicado: (2021)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
por: Heidel, F., et al.
Publicado: (2020)

A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
por: Cothran, Thomas P., et al.
Publicado: (2020)

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021)

Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch
por: Lan, Yuejia, et al.
Publicado: (2022)

The therapeutic effect and mechanism of parthenolide in skeletal disease, cancers, and cytokine storm
por: Zhu, Sipin, et al.
Publicado: (2023)

Arbutin Ameliorates Murine Colitis by Inhibiting JAK2 Signaling Pathway
por: Wang, Liang, et al.
Publicado: (2021)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance
por: Verweyen, Emely, et al.
Publicado: (2020)

Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm
por: You, Jia, et al.
Publicado: (2022)

Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now
por: Mohammed, Mona A.
Publicado: (2023)

The Immunology of Macrophage Activation Syndrome
por: Crayne, Courtney B., et al.
Publicado: (2019)

Screening of Microbial Natural Products and Biological Evaluation of Trichomicin as Potential Anti-Cytokine Storm Agents
por: Chen, Yu, et al.
Publicado: (2021)

Triiodothyronine (T(3)) ameliorates the cytokine storm in rats with sepsis
por: Yokoe, T, et al.
Publicado: (2000)

Candesartan could ameliorate the COVID-19 cytokine storm
por: Elkahloun, Abdel G., et al.
Publicado: (2020)

Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019
por: Nagarkatti, Prakash, et al.
Publicado: (2020)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019
por: Bifulco, Maurizio, et al.
Publicado: (2021)

Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury
por: Jin, Hua, et al.
Publicado: (2021)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis
por: Ge, Chenliang, et al.
Publicado: (2020)

Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling
por: Gajjela, Bharath Kumar, et al.
Publicado: (2022)

Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis
por: Albeituni, Sabrin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3sob9q71nfv5r48l58abo6aei